- Home
- CLSK vs PCVX Comparison
CLSK vs PCVX Comparison
Compare CLSK & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- PCVX
- Stock Information
- Founded
- CLSK 1987
- PCVX 2013
- Country
- CLSK United States
- PCVX United States
- Employees
- CLSK N/A
- PCVX N/A
- Industry
- CLSK Finance: Consumer Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- PCVX Health Care
- Exchange
- CLSK Nasdaq
- PCVX Nasdaq
- Market Cap
- CLSK 5.7B
- PCVX 6.0B
- IPO Year
- CLSK N/A
- PCVX 2020
- Fundamental
- Price
- CLSK $10.99
- PCVX $49.03
- Analyst Decision
- CLSK Strong Buy
- PCVX Strong Buy
- Analyst Count
- CLSK 11
- PCVX 7
- Target Price
- CLSK $24.23
- PCVX $101.67
- AVG Volume (30 Days)
- CLSK 31.6M
- PCVX 1.4M
- Earning Date
- CLSK 12-01-2025
- PCVX 11-04-2025
- Dividend Yield
- CLSK N/A
- PCVX N/A
- EPS Growth
- CLSK N/A
- PCVX N/A
- EPS
- CLSK 0.98
- PCVX N/A
- Revenue
- CLSK $631,937,000.00
- PCVX N/A
- Revenue This Year
- CLSK $109.84
- PCVX N/A
- Revenue Next Year
- CLSK $39.96
- PCVX N/A
- P/E Ratio
- CLSK $11.17
- PCVX N/A
- Revenue Growth
- CLSK 84.66
- PCVX N/A
- 52 Week Low
- CLSK $6.45
- PCVX $27.66
- 52 Week High
- CLSK $23.61
- PCVX $98.17
- Technical
- Relative Strength Index (RSI)
- CLSK 28.63
- PCVX 69.14
- Support Level
- CLSK $14.06
- PCVX $40.14
- Resistance Level
- CLSK $16.52
- PCVX $45.90
- Average True Range (ATR)
- CLSK 1.44
- PCVX 2.30
- MACD
- CLSK -0.87
- PCVX 0.26
- Stochastic Oscillator
- CLSK 1.01
- PCVX 91.15
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.